Replies to post #681 on Enanta Pharmaceuticals Inc (ENTA)

[DewDiligence]

Despite the use of ribavirin, the patient-discontinuation rate in TURQUOISE-2 was very low. Based on the phase-3 data (and ignoring any price differential), I would say ABBV/ENTA have a slight edge over GILD in the cirrhotic segment of the market.